









市场行情
/
股票
/
nasdaq-kod
/

Kodiak Sciences Inc

KOD

31.080USD

+3.630+13.22%

收盘 12/24, 13:00（美东）报价延迟15分钟

1.65B总市值

亏损市盈率 TTM



Kodiak Sciences Inc

31.080

+3.630+13.22%

概览公司财务分析

概览

公司

财务

分析

关于 Kodiak Sciences Inc 公司

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Kodiak Sciences Inc简介



公司代码KOD

公司名称Kodiak Sciences Inc

上市日期Oct 04, 2018

CEOPerlroth (Victor)

员工数量109

证券类型Ordinary Share

年结日Oct 04

公司地址1250 Page Mill Rd

城市PALO ALTO

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94304

电话16502810850

网址https://kodiak.com/

公司代码KOD

上市日期Oct 04, 2018

CEOPerlroth (Victor)

Kodiak Sciences Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. John A. Borgeson

Chief Financial Officer, Executive Vice President, Secretary

183.32K

+0.63%

Mr. Charles A. (Charlie) Bancroft

Independent Director

25.95K

Mr. Robert A. Profusek, J.D.

Lead Independent Director

10.00K

Dr. Richard S. Levy, M.D.

Independent Director

1.00K

Dr. Taiyin Yang, Ph.D.

Independent Director

Dr. Victor Perlroth, M.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

Dr. Felix J. Baker, Ph.D.

Independent Director

Dr. Bassil I. Dahiyat, Ph.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Mr. John A. Borgeson

Chief Financial Officer, Executive Vice President, Secretary

183.32K

+0.63%

Mr. Charles A. (Charlie) Bancroft

Independent Director

25.95K

Mr. Robert A. Profusek, J.D.

Lead Independent Director

10.00K

Dr. Richard S. Levy, M.D.

Independent Director

1.00K

Dr. Taiyin Yang, Ph.D.

Independent Director

Dr. Victor Perlroth, M.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Baker Bros. Advisors LP

32.66%

Point72 Asset Management, L.P.

4.65%

Perlroth (Victor D)

4.42%

BlackRock Institutional Trust Company, N.A.

3.93%

The Vanguard Group, Inc.

3.20%

其他

51.15%

持股股东

占比

Baker Bros. Advisors LP

32.66%

Point72 Asset Management, L.P.

4.65%

Perlroth (Victor D)

4.42%

BlackRock Institutional Trust Company, N.A.

3.93%

The Vanguard Group, Inc.

3.20%

其他

51.15%

股东类型

持股股东

占比

Hedge Fund

46.39%

Investment Advisor

17.84%

Investment Advisor/Hedge Fund

9.17%

Individual Investor

4.78%

Research Firm

1.78%

Endowment Fund

1.13%

Private Equity

1.04%

Pension Fund

0.16%

Bank and Trust

0.07%

其他

17.64%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

248

41.93M

79.39%

-9.11M

2025Q2

273

46.04M

87.25%

-8.67M

2025Q1

302

46.32M

87.78%

-8.84M

2024Q4

308

44.88M

85.29%

-7.98M

2024Q3

318

42.74M

81.24%

-12.36M

2024Q2

326

43.49M

82.78%

-12.58M

2024Q1

345

46.64M

88.83%

-7.18M

2023Q4

377

44.39M

84.60%

-13.12M

2023Q3

391

45.97M

87.64%

-8.18M

2023Q2

401

46.07M

88.00%

-6.85M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Baker Bros. Advisors LP

17.31M

32.77%

Jun 30, 2025

Point72 Asset Management, L.P.

452.70K

0.86%

-619.72K

-57.79%

Jun 30, 2025

Perlroth (Victor D)

2.70M

5.1%

+527.00K

+24.31%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

2.69M

5.08%

-148.79K

-5.25%

Jun 30, 2025

The Vanguard Group, Inc.

1.82M

3.45%

+133.49K

+7.90%

Jun 30, 2025

Adage Capital Management, L.P.

2.06M

3.89%

+730.00K

+55.06%

Jun 30, 2025

ICONIQ Capital, LLC

1.27M

2.4%

Jun 30, 2025

TCG Crossover Management, LLC

1.15M

2.17%

Jun 30, 2025

Acadian Asset Management LLC

1.97M

3.73%

+23.74K

+1.22%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Fidelity Enhanced Small Cap ETF

0.18%

iShares Micro-Cap ETF

0.11%

Vanguard US Momentum Factor ETF

0.11%

Invesco RAFI US 1500 Small-Mid ETF

0.06%

iShares Health Innovation Active ETF

0.06%

iShares Russell 2000 Value ETF

0.05%

Invesco Russell 2000 Dynamic Multifactor ETF

0.05%

ProShares Hedge Replication ETF

0.03%

ProShares UltraPro Russell2000

0.03%

Proshares Ultra Russell 2000

0.02%

Fidelity Enhanced Small Cap ETF

占比0.18%

iShares Micro-Cap ETF

占比0.11%

Vanguard US Momentum Factor ETF

占比0.11%

Invesco RAFI US 1500 Small-Mid ETF

占比0.06%

iShares Health Innovation Active ETF

占比0.06%

iShares Russell 2000 Value ETF

占比0.05%

Invesco Russell 2000 Dynamic Multifactor ETF

占比0.05%

ProShares Hedge Replication ETF

占比0.03%

ProShares UltraPro Russell2000

占比0.03%

Proshares Ultra Russell 2000

占比0.02%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Kodiak Sciences Inc的前五大股东是谁？



Kodiak Sciences Inc 的前五大股东如下：
Baker Bros. Advisors LP持有股份：17.31M，占总股份比例：32.77%。
Point72 Asset Management, L.P.持有股份：452.70K，占总股份比例：0.86%。
Perlroth (Victor D)持有股份：2.70M，占总股份比例：5.10%。
BlackRock Institutional Trust Company, N.A.持有股份：2.69M，占总股份比例：5.08%。
The Vanguard Group, Inc.持有股份：1.82M，占总股份比例：3.45%。